###begin article-title 0
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
A single cell cycle genes homology region (CHR) controls cell cycle-dependent transcription of the cdc25C phosphatase gene and is able to cooperate with E2F or Sp1/3 sites
###end article-title 0
###begin p 1
To whom correspondence should be addressed. Tel: +49 341 9725900; Fax: +49 341 9712209; Email: engeland@medizin.uni-leipzig.de
###end p 1
###begin p 2
###xml 71 72 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 229 230 229 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 270 276 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 376 377 376 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 589 595 589 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 737 743 737 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 983 989 983 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1073 1074 1073 1074 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 583 588 <span type="species:ncbi:9606">human</span>
###xml 731 736 <span type="species:ncbi:10090">mouse</span>
The cdc25C phosphatase participates in regulating transition from the G2 phase of the cell cycle to mitosis by dephosphorylating cyclin-dependent kinase 1. The tumor suppressor p53 down-regulates expression of cdc25C as part of G2/M checkpoint control. Transcription of cdc25C oscillates during the cell cycle with no expression in resting cells and maximum transcription in G2. We had identified earlier a new mechanism of cell cycle-dependent transcription that is regulated by a cell cycle-dependent element (CDE) in conjunction with a cell cycle genes homology region (CHR). The human cdc25C gene was the first example. CDE/CHR tandem elements have since been found in promoters of many cell cycle genes. Here we show that the mouse cdc25C gene is regulated by a CHR but does not hold a CDE. Therefore, it is the first identified gene with CHR-dependent transcriptional regulation during the cell cycle not relying on a CDE located upstream of it. The CHR leads to repression of cdc25C transcription early in the cell cycle and directs a release of this repression in G2. Furthermore, we find that this CHR can cooperate in cell cycle-dependent transcription with elements placed directly upstream of it binding E2F, Sp1 or Sp3 transcription factors.
###end p 2
###begin p 3
DDBJ/EMBL/GenBank accession no. AF450244
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
###xml 174 175 174 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c1">1</xref>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c2">2</xref>
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c3">3</xref>
###xml 415 416 415 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 444 450 444 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 527 528 527 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 607 608 607 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c2">2</xref>
The phase transitions of the cell division cycle are, in part, regulated through phosphorylation. The phosphatase cdc25C is a main regulator involved in transition from the G2 phase to mitosis in the cell division cycle (1,2). Microinjection of an antibody against cdc25C into HeLa cells leads to an inhibition of cell cycle progression before mitosis (3). Consistent with its function at the time of passage from G2 to mitosis, mRNA levels of cdc25C change periodically during the cell cycle. Only small amounts are found in G1 and increasing concentrations are observed in S phase with maximum levels in G2 (2).
###end p 5
###begin p 6
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c4">4</xref>
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c5">5</xref>
###xml 326 327 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 345 346 345 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 358 359 358 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 632 633 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c6">6</xref>
###xml 634 635 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c7">7</xref>
Transcriptional regulation during the mammalian cell cycle has so far been mostly associated with the function of the E2F family of transcription factors and the retinoblastoma tumor suppressor protein pRb (4,5). Heterodimers formed by E2F and DP components are able to activate transcription of cell cycle promoters in late G1 and S phase. In G0 and early G1, complex formation of the retinoblastoma tumor suppressor pRb family of proteins with E2F/DP represses transcription. Transition from this repression in the early phase of the cell cycle to activation at later times is controlled by phosphorylation of pRb-family members (6,7).
###end p 6
###begin p 7
###xml 333 339 333 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 341 349 341 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin A</italic>
###xml 351 360 351 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin B2</italic>
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc2</italic>
###xml 535 536 535 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 542 543 542 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c10">10</xref>
###xml 687 688 687 688 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 694 695 694 695 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c11">11</xref>
###xml 1143 1147 1143 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc2</italic>
###xml 1152 1160 1152 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin A</italic>
###xml 1231 1233 1231 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c12">12</xref>
More recently we have identified another mechanism by which gene transcription can be regulated in a cell cycle-dependent manner. This mechanism employs a tandem transcriptional element composed of the cell cycle-dependent element (CDE) and the cell cycle genes homology region (CHR). The fluctuations in mRNA levels from genes like cdc25C, cyclin A, cyclin B2 and cdc2 (cdk1) are dependent on differential transcription due to these tandem repressor elements in their promoters. CDE/CHR sites regulate the promoters by repression in G0 and G1 and release from repression later in the cell cycle (8-10). Both halves of the CDE/CHR element are required for transcriptional repression in G0 and G1. Inactivation of either the CDE or the CHR leads to deregulation of transcription with high expression levels already in early phases of the cell cycle. The proteins regulating through CDE/CHR elements have so far only been described poorly. A factor called CDF-1, which is different from E2F, has been shown by one group to bind to some CDE/CHR elements (11). However, this factor has resisted cloning and further molecular characterization. The cdc2 and cyclin A promoters were shown to bind E2F to the CDE half of the CDE/CHR site (12).
###end p 7
###begin p 8
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 194 197 194 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 279 282 279 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E1b</italic>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c13">13</xref>
###xml 349 355 349 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 401 407 401 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 511 517 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 534 535 534 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c14">14</xref>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c15">15</xref>
###xml 7 12 <span type="species:ncbi:9606">human</span>
In the human cdc25C promoter a recognition site for the tumor suppressor p53 has been described. This site can bind p53 and is able to activate transcription in response to co-transfection of a p53-expressing plasmid, at least when artificially placed adjacent to the adenovirus E1b minimal promoter (13). We have demonstrated that transcription of cdc25C is repressed by p53. This down-regulation of cdc25C is not contingent upon the p53 site in its promoter but depends on CCAAT boxes. The down-regulation of cdc25C is part of the G2/M checkpoint control by p53 (14,15).
###end p 8
###begin p 9
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 307 316 307 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin B2</italic>
###xml 398 399 398 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 489 490 489 490 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c16">16</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c17">17</xref>
###xml 848 850 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c18">18</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c20">20</xref>
The trimeric nuclear transcription factor Y (NF-Y) binds to these CCAAT boxes and is the major activator for CDE/CHR-regulated promoters (8). NF-Y binding activity varies during the cell cycle. However, it only contributes as a general activator to the typical cell cycle-dependent expression of genes like cyclin B2. Concentration of its NF-YA subunit decreases only after the peak expression in G2 of the CDE/CHR genes has already been reached. NF-Y binding activity is also present in G1, at which time these cell cycle genes are not expressed (16). Another important transcriptional activator is Sp1. It binds to GC boxes and is the first identified member of a larger family of transcription factors (17). Sp1 was also recognized as a factor involved in transcription of the cell cycle genes, particularly through cooperation with E2F or pRb (18-20).
###end p 9
###begin p 10
Here we describe the first CHR element that does not rely on intact CDE or E2F sites upstream of it to confer cell cycle-dependent transcription. The cdc25C CHR can cooperate with E2F and Sp1/3 sites in regulating promoter activity during the cell cycle.
###end p 10
###begin title 11
MATERIALS AND METHODS
###end title 11
###begin title 12
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
Cloning of the cdc25C promoter and plasmid constructs
###end title 12
###begin p 13
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 661 664 661 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
###xml 669 672 669 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 1077 1083 1077 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1146 1148 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c15">15</xref>
###xml 90 95 <span type="species:ncbi:10090">Mouse</span>
###xml 1071 1076 <span type="species:ncbi:9606">human</span>
The cdc25C genomic DNA upstream of the start codon was amplified from the adaptor-ligated Mouse GenomeWalker library (Clontech, Palo Alto, CA) by primer walking. The series of PCRs started with two nested gene-specific primers derived from the 5' end of the cDNA (GenBank accession nos L16926 and L16994): CDCMO2-3', 5'-ACAGAATGCTTAGGTTTGCCGAGTCG-3'; CDMO1-3', 5'-GTCTAGGTACCTCTAGAGTGGGATAGGTCCTGTAGACATGAC-3'. After the last walking step the m25C-wt-luci construct was obtained by PCR amplification with the primers M25C-5', 5'-GACCCAAGCTTCTGGTCTGCTGCCACCACCATCACTAAACCCGCC-3', and M25C-3', 5'-CTGTAGCCATGGCTTCAGAGTCTTCACCGAGGGAGGTGGG-3', followed by cloning (HindIII/NcoI) in pGL3-Basic (Promega, Mannheim, Germany). In two independent experiments from different genomic DNA samples clones were obtained and sequencing of both strands yielded an identical sequence for both clones, which was submitted to the database (GenBank accession no. AF450244). The m25C-wt-luci 1302 bp promoter construct drives expression of firefly luciferase as reporter. The sequence of the human cdc25C promoter, including the segment close to the coding sequence (15), was described earlier (GenBank accession nos AY046902 and Z29077).
###end p 13
###begin p 14
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c16">16</xref>
###xml 791 798 791 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
###xml 821 830 821 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin B2</italic>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c10">10</xref>
###xml 963 969 963 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1005 1007 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c14">14</xref>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c15">15</xref>
###xml 815 820 <span type="species:ncbi:10090">mouse</span>
Promoter mutants were produced by PCR-based mutagenesis on the basis of m25C-wt-luci. The mutant M1 was created employing the primers M1-for, 5'-TTGTTGAGctgtcGGAAGGTTTGAATGGTCAGACC-3', and M1-rev, 5'-CAAACCTTCCgacagCTCAACAACCTATCACCAC-3' (mutations are indicated by lower case letters). The other constructs mutated in the region of the CDE were obtained by PCR with equivalent primers. The construct M6 was also produced by PCR using primers M6-for, 5'-GGAAGGTgcatATGGTCAGACCTCTGGCTGTTG-3', and M6-rev, 5'-CTGACCATatgcACCTTCCACTCTCTCAACAAC-3'. The other plasmids mutated in the region of the CHR were created with equivalent primers. The plasmid YA13m29 was provided by Roberto Mantovani and expresses a dominant-negative subunit A of NF-Y (16). pRL-null (Promega) contains a cDNA encoding Renilla luciferase. The mouse cyclin B2 promoter driving expression of firefly luciferase in B2-Luci plasmid (10) as well as reagents investigating the influence of p53 on cdc25C expression were described earlier (14,15).
###end p 14
###begin p 15
###xml 102 118 102 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 214 217 214 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 219 222 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 102 118 <span type="species:ncbi:562">Escherichia coli</span>
A plasmid was created to express recombinant full-length human DP-1 (GenBank accession no. L23959) in Escherichia coli as a fusion protein with six histidine amino acids at the C-terminus. The cDNA was cloned as a NcoI/BglII fragment into pQE-60 (Qiagen, Hilden, Germany) after PCR amplification from a cDNA library (Clontech) with the following two primers: forward, 5'-TTCATGCCATGGCAAAAGATGCCGGTC-3'; reverse, 5'-ACCAGAAGATCTGTCGTCCTCGTCATTCTCG-3'.
###end p 15
###begin p 16
All plasmid DNAs were purified through anion exchange columns (Qiagen) and confirmed by restriction analysis and sequencing.
###end p 16
###begin title 17
Cell culture and transfections
###end title 17
###begin p 18
###xml 113 114 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 204 208 <span type="species:ncbi:9913">calf</span>
NIH 3T3 cells were obtained from DSMZ (Braunschweig, Germany) and cultured in a humidified atmosphere with 10% CO2 at 37degreesC with Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS; Biochrom, Berlin, Germany).
###end p 18
###begin p 19
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 212 216 <span type="species:ncbi:4681">Leek</span>
###xml 649 654 <span type="species:ncbi:10090">mouse</span>
For cell cycle analyses, 4 x 104 cells were plated per well in 1 ml medium on 12-well plates and cultured overnight before transfection. Transfections were carried out in 4-fold using 6 microl Pfx-3 (Invitrogen, Leek, The Netherlands) with 2 microg luciferase reporter construct and 40 ng of pRL-null vector (Promega) in 1 ml Optimem transfection medium (Gibco, Eggenstein, Germany) per well. Cells were incubated for 4 h before replacing transfection medium with DMEM containing 10% FCS. Cells were then cultured for 1 day in this medium before starvation in DMEM without FCS for 60 h. After this time cells were harvested for 0 h time points. The mouse fibroblasts were stimulated with 20% FCS in DMEM to re-enter the cell cycle and subsequently analyzed at indicated times.
###end p 19
###begin p 20
###xml 112 113 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
Transfections using the dominant-negative form of NF-YA were carried out in triplicate. In 24-well plates 5 x 104 cells were plated per well in 0.5 ml medium. Cells were cultured overnight before transfection. Transfection was carried out using 1 microl Fugene 6 (Roche, Mannheim, Germany) with 125 ng luciferase reporter construct, 2.5 ng of pRL-null vector and increasing amounts of construct YA13m29.
###end p 20
###begin p 21
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c15">15</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c21">21</xref>
###xml 213 214 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 490 491 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 717 724 711 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
Co-transfection experiments with p53 wild-type or mutant expression plasmids and the mouse cdc25C reporter were carried out in SaOS-2 cells (DSMZ) (15,21). Cells were cultured in a humidified atmosphere with 5% CO2 at 37degreesC with McCoy's 5A modified medium (Biochrom) supplemented with 15% FCS. Transfection was carried out in triplicate using lipofection with Fugene 6 (Roche) according to the manufacturer's instructions. Exponentially growing cells were plated at a density of 5 x 104/well in 0.5 ml medium in 24-well plates. Cells were cultured overnight before transfection. m25C-wt-luci construct (250 ng) was co-transfected with 25 ng of constructs expressing wild-type or mutant p53 proteins and 25 ng of Renilla luciferase expression vector (pRL-null; Promega) as an internal control. DNA amount was held constant in all experiments by adjusting with pcDNA3.1/His C (Invitrogen).
###end p 21
###begin title 22
Luciferase assays
###end title 22
###begin p 23
###xml 163 170 163 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
Luciferase activities were assayed with the Dual Luciferase Assay System (Promega) as suggested by the manufacturer. Firefly luciferase activity was normalized to Renilla luciferase activity to compensate for variability in transfection efficiencies.
###end p 23
###begin title 24
Fluorescence activated cell sorting (FACS) analyses
###end title 24
###begin p 25
Cells were harvested, washed in PBS/EDTA (1 mM) and fixed with 75% ethanol in PBS/EDTA for >/=12 h at 4degreesC, and subsequently centrifuged and resuspended in 1 ml PBS/EDTA containing 50 microg/ml RNase A (Sigma, Munchen, Germany). Propidium iodide (Sigma) staining followed at a final concentration of 40 microg/ml. Cells were filtered through a 35 microm pore size cell strainer (Falcon, Heidelberg, Germany). Flow cytometry was performed with a FACSCalibur instrument (Becton Dickinson, Heidelberg, Germany). A total of at least 10 000 cells per run was analyzed with the CELLQuest software (Becton Dickinson).
###end p 25
###begin title 26
Electrophoretic mobility-shift assays (EMSAs)
###end title 26
###begin p 27
###xml 133 135 129 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Oligonucleotide probes were labeled by filling in 5' overhangs using the Klenow fragment of DNA polymerase in the presence of [alpha-32P]deoxycytidine-5'-triphosphate. The labeled oligonucleotides were purified using the Nucleotide Removal Kit (Qiagen) according to the manufacturer's instructions.
###end p 27
###begin p 28
###xml 165 166 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 589 591 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c22">22</xref>
###xml 777 779 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c23">23</xref>
For Sp1/3 EMSAs HeLa nuclear extract with approximately5 microg of protein were incubated for 15 min at room temperature in 10 mM Tris pH 7.5, 0.5 mM EDTA, 1 mM MgCl2, 50 mM NaCl, 0.5 mM DTT, 6% glycerol and 0.75 microg of polydeoxyinosinic-deoxycytidylic acid, poly(dI-dC) (Sigma) in a total volume of 15 microl. Antibodies specific for Sp1 (sc-420) and Sp3 (sc-644) transcription factors were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and incubated with protein mixtures prior to addition of probe. For Sp1/3 shifts GC-box oligo_nucleotide was used as a positive control (22). After probe addition, reactions were incubated for 20 min at room temperature. The protein-DNA complexes were separated on native 4.5% polyacrylamide gels at 15degreesC as described (23). Gels were dried and visualized using a FLA-3000 Fujifilm phosphorimaging system.
###end p 28
###begin p 29
###xml 195 200 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B-myb</italic>
###xml 211 213 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c24">24</xref>
###xml 255 257 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c25">25</xref>
###xml 287 293 275 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 189 194 <span type="species:ncbi:10090">mouse</span>
###xml 281 286 <span type="species:ncbi:10090">mouse</span>
E2F EMSAs were carried out with approximately300 ng recombinant E2F1-GST and DP1-His per assay. Oligonucleotides employed to shift E2F as wild-type and mutant control were derived from the mouse B-myb promoter (24) and used in EMSAs as published earlier (25). The sequences of the mouse cdc25C gene specific EMSA oligonucleotides were as follows: Sp25C, 5'-GGAACATGACCCCGCCCCCTAACCAATC-3' and 5'-GATTGGTTAGGGGGCGGGGTCATGTT-3'; Sp25Cmut, 5'-GGAACATGACTATATATCCTAACCAATC-3' and 5'-GATTGGTTAGGATATATAGTCATGTT-3'; wt, 5'-GGTTGTTGAGAGAGTGGAAGGTTTGAATGGTCAGAC-3' and 5'-GTCTGACCATTCAAACCTTCCACTCTCTCAACAA-3'. The sequences of the mutant EMSA probes can be derived on this basis from mutations indicated in the figures.
###end p 29
###begin p 30
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c26">26</xref>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c27">27</xref>
###xml 302 308 302 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 187 193 <span type="species:ncbi:562">E.coli</span>
###xml 302 308 <span type="species:ncbi:562">E.coli</span>
Nuclear extracts from HeLa cells were prepared as described and were a generous gift from Reinhard Luhrmann (26). E2F-1 as glutathione-S-transferase (GST) fusion protein was expressed in E.coli from the plasmid pGST20TE2F-1 constructed and provided by Kristian Helin (27). The protein was expressed in E.coli using the QIAexpress System (Qiagen). DP-1-His was purified with Ni-NTA-agarose (Qiagen) according to manufacturer's instructions. After isolation, DP-1 was dialyzed against 50 mM Tris pH 7.5, 5 mM DTT, 100 mM NaCl and supplemented with 50% glycerol.
###end p 30
###begin title 31
RESULTS
###end title 31
###begin title 32
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
Cell cycle-dependent transcription from the cdc25C promoter
###end title 32
###begin p 33
###xml 2 8 2 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f1">1</xref>
###xml 176 182 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 170 175 <span type="species:ncbi:10090">mouse</span>
A cdc25C promoter construct driving luciferase expression shows cell cycle dependence (Fig. 1). To obtain DNA sequence information necessary to create this construct the mouse cdc25C gene upstream of the coding region was amplified by primer walking starting from the 5' end of the cDNA. With primers derived from the subsequent sequencing a DNA segment of 1302 bp upstream of the first coding ATG was amplified and cloned into a vector that could be used to drive luciferase reporter expression.
###end p 33
###begin p 34
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 93 94 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f1">1</xref>
###xml 503 504 479 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 529 530 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f1">1</xref>
###xml 544 550 520 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 618 627 594 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin B2</italic>
###xml 707 708 683 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 716 722 692 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 793 802 769 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin B2</italic>
###xml 809 810 785 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f1">1</xref>
###xml 831 837 807 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 917 918 893 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c2">2</xref>
###xml 919 921 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c28">28</xref>
###xml 989 995 965 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1048 1049 1024 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 1050 1052 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c29">29</xref>
###xml 900 905 <span type="species:ncbi:9606">human</span>
###xml 910 915 <span type="species:ncbi:10090">mouse</span>
###xml 983 988 <span type="species:ncbi:10090">mouse</span>
###xml 1032 1037 <span type="species:ncbi:9606">human</span>
Expression from the cdc25C promoter is low in resting cells compared with expression in the G2/M phase of the cell cycle (Fig. 1A). Stimulation of expression is approximately14-fold comparing minimum expression before addition of serum with maximum expression at 28 h after restimulation of cell division. Cell cycle distribution of cells was followed by FACS analysis of DNA stained cells with the maximum for S phase cells at approximately18 h after serum restimulation with a subsequent increase in G2/M cell population (Fig. 1B). Timing of cdc25C expression during the cell cycle is similar to expression from the cyclin B2 promoter, which is reasonable since products of both genes are needed in late G2 phase. cdc25C transcription starts earlier and reaches its peak level shortly after cyclin B2 (Fig. 1). Expression of the cdc25C reporter matches expression from the chromosomal gene in both human and mouse (2,28). Stimulation factor, timing and levels of expression of the mouse cdc25C reporter are similar to that of the human promoter (8,29).
###end p 34
###begin title 35
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 10 15 <span type="species:ncbi:9606">human</span>
Mouse and human cdc25C promoters share limited homology
###end title 35
###begin p 36
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 239 245 239 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f2">2</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c30">30</xref>
###xml 849 850 849 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 968 969 968 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f2">2</xref>
###xml 1316 1317 1316 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f2">2</xref>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
###xml 327 332 <span type="species:ncbi:10090">mouse</span>
###xml 337 342 <span type="species:ncbi:9606">human</span>
###xml 548 553 <span type="species:ncbi:10090">mouse</span>
###xml 558 563 <span type="species:ncbi:9606">human</span>
###xml 665 670 <span type="species:ncbi:9606">human</span>
###xml 1037 1042 <span type="species:ncbi:10090">mouse</span>
###xml 1295 1300 <span type="species:ncbi:10090">mouse</span>
The activating and cell cycle-regulatory sites in the human cdc25C promoter have been mapped (8). After finding that the mouse 1302 bp genomic DNA fragment upstream of the coding region is sufficient to drive transcription typical for the cdc25C gene we sought to identify the regulatory elements. We compared sequences of the mouse and human promoters (Fig. 2 and Supplementary Material). The overall homology between the two sequences is low. In the promoter region, 756 nt upstream of the first codon, only 357 bases or 47% are identical in the mouse and human promoters (Supplementary Material). However, a few segments are conserved in both promoters. For the human promoter, NF-Y and Sp1 sites had been identified as main activating elements (30). The CDE/CHR tandem element is responsible for cell cycle-dependent transcriptional regulation (8). Two of the NF-Y-binding CCAAT boxes are conserved, both with regard to sequence and distance from each other (Fig. 2). The third, most upstream of the CCAAT boxes, is not found in the mouse promoter. Another potentially activating site, the GC box with a consensus for binding Sp1 and Sp3 proteins, is found in both promoters. Most interestingly, the region of the CHR cell cycle element is conserved but the adjacent CDE is not found in the mouse promoter (Fig. 2).
###end p 36
###begin title 37
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
NF-Y is the main transcriptional activator for cdc25C transcription
###end title 37
###begin p 38
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c16">16</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c30">30</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c31">31</xref>
###xml 393 399 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 425 426 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f3">3</xref>
###xml 571 577 571 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
Transcription of many cell cycle genes is regulated by NF-Y as the predominant activator (8,16,30,31). A simple method to test for the activation by the trimeric NF-Y factor is to employ a dominant-negative subunit of it. We co-transfected, into normally growing NIH 3T3 cells, increasing amounts of a plasmid carrying a dominant-negative mutant of NF-YA (YA13m29) together with the wild-type cdc25C reporter construct (Fig. 3). More than 60% of the activity is lost at the highest concentration of the dominant-negative mutant. This indicates that more than half of the cdc25C promoter activity is dependent on activation by NF-Y.
###end p 38
###begin title 39
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
p53 down-regulates transcription of cdc25C independent of a p53 consensus binding site
###end title 39
###begin p 40
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f2">2</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c13">13</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c15">15</xref>
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f2">2</xref>
###xml 433 439 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f4">4</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c21">21</xref>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c32">32</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c33">33</xref>
###xml 747 753 747 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 916 917 916 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f2">2</xref>
###xml 1006 1012 1006 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1023 1025 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c15">15</xref>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 145 150 <span type="species:ncbi:9606">human</span>
###xml 282 287 <span type="species:ncbi:9606">human</span>
###xml 292 297 <span type="species:ncbi:10090">mouse</span>
###xml 427 432 <span type="species:ncbi:10090">mouse</span>
###xml 741 746 <span type="species:ncbi:10090">mouse</span>
###xml 1000 1005 <span type="species:ncbi:9606">human</span>
The mouse cdc25C promoter does not contain a p53 consensus binding site (Fig. 2 and Supplementary Material). The site, which can bind p53 in the human promoter, is located centered around nucleotide -787 relative to the translational start (13,15). This region is not homologous in human and mouse promoters (Fig. 2). However, transfection of SaOS-2 cells with a plasmid expressing p53 yields a 6.8-fold down-regulation of the mouse cdc25C promoter luciferase reporter when wild-type p53 is compared with a mutant form of p53 (Fig. 4). The mutant used as a control is an altered form with amino acid changes P72R and V143A, which lead to its inability to serve as a transcription factor (21,32,33). Down-regulation of transcription from the mouse cdc25C promoter by the p53 tumor suppressor proves that this regulation is independent of a p53 binding site in the promoter since this promoter lacks such a site (Fig. 2). This result is consistent with our previous observations and conclusions on the human cdc25C promoter (15).
###end p 40
###begin title 41
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
The CHR is the major site responsible for regulating cell cycle-dependent transcription of mouse cdc25C
###end title 41
###begin p 42
###xml 366 367 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 505 506 505 506 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 566 567 566 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 572 573 572 573 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 613 619 613 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 635 636 635 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 248 253 <span type="species:ncbi:10090">mouse</span>
In order to elucidate the impact of potential cell cycle elements we mutated the putative CHR and the region upstream of it in reporter constructs and tested them for cell cycle-dependent transcription. These constructs were transfected in NIH 3T3 mouse fibroblasts and expression assayed by luciferase activity. Cells were starved by serum deprivation to test for G0 expression and restimulated by serum re-addition to the medium for 24 h to obtain promoter activities for a cell population enriched in G2. Stimulation of transcription of 17 mutant promoters from G0 to G2 was measured relative to the wild-type cdc25C promoter (Fig. 5). Average stimulation of 13.6-fold for wt-m25C-luci was set to 100%.
###end p 42
###begin p 43
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 215 216 215 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 233 234 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 488 494 488 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
Mutant promoters M6 to M11 have lost most of their ability to drive cell cycle-dependent transcription (Fig. 5A). These mutant promoters all contain changes in the putative CHR that lead to a lack of repression in G0. Activities in G2 stay at the same level as for the wild-type construct, whereas mutant reporter activities increase in resting cells. In mutants M6 to M11 this behavior results in a drop of cell cycle regulation of transcription to about one-fifth that of the wild-type cdc25C promoter. Even single nucleotide mutations as in M8 and M11 display a substantial loss of regulation. Therefore, this site is indeed a CHR.
###end p 43
###begin p 44
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c10">10</xref>
###xml 525 526 525 526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 564 565 564 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 663 669 663 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 844 845 844 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 911 912 911 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 1163 1169 1163 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1274 1280 1274 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1355 1356 1355 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
###xml 1157 1162 <span type="species:ncbi:10090">mouse</span>
###xml 1268 1273 <span type="species:ncbi:9606">human</span>
Functional CHR elements have, until now, only been described in conjunction with CDEs. The respective sequence in the mouse cdc25C promoter upstream of the CHR is different from any CDE identified so far (8-10). Still, mutation of this region leads to a change in regulation. An alteration in cell cycle-dependent transcription is seen in mutants M1 and M4 with about half the regulation lost. Like regulation of mutants M6 to M11, changes in cell cycle transcription of M1 and M4 are also due to an increase of activity in G0 while transcriptional activation in G2 stays at the same level as activity for the wild-type promoter. In comparison with the wild-type cdc25C promoter, mutants M2 and M3 do not give a significant change in regulation; and the mutation introduced in M5 even shows an improved cell cycle-regulated transcription (Fig. 5A). Summing up the results from the mutations presented in Figure 5A, it is obvious that changes in the CHR result in a much stronger alteration of cell cycle-dependent transcription than mutations in the region upstream from it, where in other promoters a CDE is found. If the region upstream of the CHR in the mouse cdc25C promoter is changed to a CDE-like sequence, as in mutant M16, or even mutated to the CDE from the human cdc25C promoter, as in M12, cell cycle-regulated transcription is improved (Fig. 5B).
###end p 44
###begin p 45
###xml 79 80 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 103 104 103 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 235 236 235 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 385 386 385 386 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 558 564 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 714 715 714 715 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 759 760 759 760 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 767 768 767 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 881 887 881 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 910 911 910 911 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
All deregulated promoter mutants show an increase in luciferase activities in G0 instead of a loss in G2. Mutants such as M5 and M15, for which a stronger regulation than for the wild-type construct is observed, have an expression in G0 at a similar level to the wild-type promoter. Their change in stimulation compared with wild type results from an increase of promoter activity in G2. Mutant M16 is different in that it shows a lower than wild-type activity in resting cells, thereby displaying a increased fold induction in comparison with the wild-type cdc25C promoter. In contrast, the reduced cell cycle-dependent transcriptional regulation seen in mutants M1 and M4 is due to an increase in expression in G0 rather than lower levels of expression in G2 (Fig. 5 and data not shown). Each deregulated mutant promoter gives activities at the elevated level at which wild-type cdc25C promoter activity in G2 is observed. This implies a loss of repression rather than a reduction of activation when cell cycle elements are mutated.
###end p 45
###begin title 46
The CHR is able to cooperate in regulating cell cycle-dependent transcription with CDE, E2F or Sp1/3 sites
###end title 46
###begin p 47
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c10">10</xref>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 555 556 555 556 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 600 601 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 691 692 691 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 738 744 738 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 910 911 910 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 376 381 <span type="species:ncbi:10090">mouse</span>
###xml 732 737 <span type="species:ncbi:10090">mouse</span>
###xml 894 899 <span type="species:ncbi:9606">human</span>
All CHR elements identified so far to be relevant for cell cycle-dependent transcription are found in conjunction with a CDE site 4 nt upstream of the CHR (8-10). Therefore, we tested if the CDE from the human cdc25C promoter, introduced in the proper position with mutant M12 to create the CDE/CHR tandem element, would lead to cell cycle transcription in the context of the mouse promoter. The mutant M12 with an intact CDE/CHR is not only transcribed in a cell cycle-dependent manner, but displays an even stronger regulation with a lower activity in G0 compared with the wild-type promoter (Fig. 5B). As a control, mutation of the CHR in this CDE/CHR context has been described earlier (8). This indicates that the CHR from the mouse cdc25C promoter can cooperate with a CDE artificially placed in tandem with it. Yet the CDE alone cannot regulate cell cycle-dependent transcription in the human promoter (8).
###end p 47
###begin p 48
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B-myb</italic>
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c25">25</xref>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
An E2F site originating from the mouse B-myb promoter (25) was another element we chose to test in tandem with this CHR. Mutant promoter M13 with an E2F/CHR site shows a stronger cell cycle transcription than the wild-type promoter with just a CHR (Fig. 5B). As a control that the cell cycle-dependence of this new tandem element is contingent upon the CHR and not simply attributable solely to the introduced E2F site we changed the CHR in this context. M14 as the corresponding mutant has almost no ability to direct cell cycle-dependent transcription (Fig. 5B). Therefore, E2F and CHR sites cooperate in the M13 mutant promoter to regulate cell cycle-dependent transcription.
###end p 48
###begin p 49
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B-myb</italic>
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f6">6</xref>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 582 588 582 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 769 770 769 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f6">6</xref>
###xml 1062 1063 1062 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 1069 1070 1069 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f6">6</xref>
The ability of the mutant sites to bind E2F protein was tested in EMSAs. As a control, an oligonucleotide from the B-myb promoter carrying an E2F site was used by incubating it with E2F-1 and DP-1. This binding was compared with the same oligonucleotide with its E2F site mutated (Fig. 6, lanes 1 and 2). E2F does not bind to the wild-type cdc25C promoter oligonucleotide nor to probes mutated in the CHR and upstream from it (lanes 3-6). However, when an E2F site is introduced upstream of the CHR, binding similar to that of the B-myb probe is also observed in the context of the cdc25C promoter (M13 and lane 1). Binding to this E2F site is not dependent on an intact CHR since mutant oligonucleotide M14 is still able to bind E2F with similar affinity as M13 (Fig. 6). Taken together with functional assays this indicates that, on the one hand, an E2F site can bind E2F-1/DP-1 heterodimers even in the absence of an intact CHR in tandem with it. But, on the other hand, this isolated E2F site is not able to regulate cell cycle-dependent transcription (Figs 5B and 6).
###end p 49
###begin p 50
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
Two other mutants were tested to see if changing the region upstream of the CHR to DNA binding sites for Sp1 and Sp3 would diminish cell cycle-dependent transcription, like a random mutation did in M1 and M4 mutants (Fig. 5A). Unexpectedly, both mutants M15 and M16, which were created to place Sp1/3 sites upstream of the CHR, do not show a reduced cell cycle-dependent transcription. Instead, cell cycle transcription is even more pronounced (Fig. 5B). Additional mutation of the CHR in the M16 construct to the M17 mutant leads to a total loss of cell cycle-dependent transcription (Fig. 5B). This proves that introduction of Sp1/3 sites alone is not sufficient to create a cell cycle element.
###end p 50
###begin p 51
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 278 284 278 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f6">6</xref>
###xml 427 433 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f6">6</xref>
###xml 774 780 774 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 796 797 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 803 804 803 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f6">6</xref>
We tested protein binding to the Sp1/3 sites that were introduced in the cdc25C promoter and could support cell cycle-dependent transcription. Because of the similarity between E2F and Sp1/3 sites we used E2F-1/DP-1 proteins in EMSAs. The M16 and M17 mutants, both based on the cdc25C promoter and mutated to an Sp1/3 site, were able to shift a weak band compared with bona fide E2F sites (Fig. 6). However, mutant M15, also a cdc25C promoter segment with an Sp1/3 site, cannot yield a band with E2F (Fig. 6). Since mutants M15 and M16 showed cell cycle-dependent transcription and mutant M17 did not, and only mutants M16 and M17 but not M15 could bind E2F, it can be excluded that only E2F is responsible for cell cycle transcription through Sp1/3 sites introduced in the cdc25C promoter (Figs 5B and 6).
###end p 51
###begin p 52
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 272 278 272 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 543 549 543 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 652 653 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 798 799 798 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 916 917 916 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 1082 1083 1082 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 1152 1158 1152 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1292 1293 1292 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
Sp1 and Sp3 protein binding to wild-type and mutant oligonucleotides was tested by EMSA from HeLa cell nuclear extract (Fig. 7). The GC control probe provides mobilities for the Sp1 and Sp3 protein-DNA complexes (Fig. 7A, lanes 1 and 2). A wild-type DNA fragment from the cdc25C promoter cell cycle regulatory region containing the CHR does not bind Sp1 or Sp3 (Fig. 7A, lane 3). Probes based on the same oligonucleotide with mutations in the CHR or the region upstream of it (M1, M4, M6 and M9) do not give an Sp1/3 shift (Fig. 7A). However, cdc25C promoter mutants engineered to contain Sp1/3 sites shift bands with the mobility of Sp1 and Sp3 (Fig. 7A, M15-M17). To confirm the identity of Sp1 and Sp3 shifts, we carried out competition EMSAs and experiments including specific antibodies (Fig. 7B). An oligonucleotide (GC) which can bind both Sp1 and Sp3 factors shifts two bands that can be self-competed (Fig. 7B, lanes 1 and 2). The bands are reduced in intensity or disappear and supershifted complexes become visible when antibodies specific for Sp1 or Sp3 are added (Fig. 7B, lanes 3 and 4). The same Sp1 and Sp3 complexes are shifted by the cdc25C promoter mutants M14 to M17. Competition with the Sp1/3-binding GC oligonucleotide abrogates binding of the two specific bands (Fig. 7B, lanes 5-12).
###end p 52
###begin title 53
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
Sp1 and Sp3 can bind to an activator site in the cdc25C promoter
###end title 53
###begin p 54
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f2">2</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c34">34</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c30">30</xref>
###xml 546 552 546 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 640 641 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 660 666 660 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 798 799 798 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 918 919 918 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 1000 1006 1000 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
###xml 149 154 <span type="species:ncbi:9606">human</span>
###xml 540 545 <span type="species:ncbi:10090">mouse</span>
There is one putative Sp1/3 site in the cdc25C promoter centered around nucleotide -709 in the mouse promoter (Fig. 2). The homologous region in the human promoter, containing a sequence for a classical Sp1 site (34), had been deleted with a loss of about one-third of the activity and thereby shown to be relevant for activation (30), but protein binding to this site remained to be tested. In EMSAs the GC oligonucleotide and a specific antibody were used as positive controls. The Sp25C probe containing the putative Sp1/3 site from the mouse cdc25C promoter was employed to compete with the two complexes specific for Sp1 and Sp3 (Fig. 7C, lanes 1-4). The cdc25C promoter segment used as a probe was able to shift Sp1 and Sp3 factors whereas a mutant of the Sp1/3 site (Sp25Cmut) did not (Fig. 7C, lanes 5 and 9). Supershift with the antibody against Sp1 and competition with self and the GC oligonucleotide (Fig. 7C, lanes 6-8) are consistent with the notion that the putative Sp1/3 site in the cdc25C promoter is indeed a binding site for Sp1 and Sp3.
###end p 54
###begin title 55
DISCUSSION
###end title 55
###begin p 56
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c10">10</xref>
###xml 197 203 197 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f2">2</xref>
###xml 289 295 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c10">10</xref>
###xml 698 699 698 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 720 728 720 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin A</italic>
###xml 730 734 730 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc2</italic>
###xml 745 751 745 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 954 960 954 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1155 1156 1155 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c8">8</xref>
###xml 1213 1219 1213 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1290 1291 1290 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f2">2</xref>
###xml 1536 1538 1536 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c11">11</xref>
###xml 1599 1605 1599 1605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1798 1804 1798 1804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1836 1845 1836 1845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin B2</italic>
###xml 1856 1858 1856 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c10">10</xref>
###xml 191 196 <span type="species:ncbi:10090">mouse</span>
###xml 245 250 <span type="species:ncbi:9606">human</span>
###xml 283 288 <span type="species:ncbi:9606">human</span>
###xml 452 457 <span type="species:ncbi:10090">mouse</span>
###xml 739 744 <span type="species:ncbi:9606">human</span>
###xml 948 953 <span type="species:ncbi:9606">human</span>
###xml 1041 1046 <span type="species:ncbi:10090">mouse</span>
###xml 1197 1202 <span type="species:ncbi:9606">human</span>
###xml 1207 1212 <span type="species:ncbi:10090">mouse</span>
###xml 1382 1387 <span type="species:ncbi:9606">human</span>
###xml 1583 1588 <span type="species:ncbi:10090">mouse</span>
###xml 1593 1598 <span type="species:ncbi:9606">human</span>
###xml 1712 1717 <span type="species:ncbi:10090">mouse</span>
###xml 1792 1797 <span type="species:ncbi:9606">human</span>
###xml 1830 1835 <span type="species:ncbi:10090">mouse</span>
###xml 2074 2079 <span type="species:ncbi:10090">mouse</span>
All CHR elements identified until now need a CDE in tandem with them to be functional (8-10). We describe here for the first time a CHR that does not have a CDE 4 nt upstream. The CHR in the mouse cdc25C promoter is homologous to the CHR in the human promoter (Fig. 2). However, the human cdc25C CHR can only repress and, thereby, regulate transcription during the cell cycle while the CDE 5' from it is intact (8). The nucleotide sequence 5' from the mouse cdc25C CHR is different from any known CDE (8-10). Nevertheless, mutation of this segment reduces cell cycle-dependent transcription in mutants M1 to M4 to some extent, but it is clearly not as pronounced as with mutations in the CHR (Fig. 5A). In contrast, for cyclin A, cdc2 and human cdc25C promoters mutations in CDEs and CHRs had equally strong effects on deregulation of cell cycle-dependent transcription. Furthermore, an extensive and detailed mutational analysis of the CDE in the human cdc25C promoter shows that a mutation from 5'-GGCGG-3' to 5'-AGTGG-3', as found in the mouse promoter described here, would clearly result in a loss of cell cycle-dependent transcriptional regulation (8). Comparison of the CHR elements in the human and mouse cdc25C promoters reveals that the homology extends beyond the CHR core (Fig. 2). However, a detailed study testing various nucleotides in and around the CHR core in the human promoter has shown that nucleotides outside the core 5'-TTTGAA-3' are not needed for cell cycle-dependent transcriptional regulation in this assay (11). The difference in CDE/CHR combinations of mouse and human cdc25C promoters is not likely the result of a general species difference since CDE/CHR-regulated promoters from mouse have been described with CDEs that conform the CDE consensus derived from human cdc25C CDE, e.g. as seen in the mouse cyclin B2 promoter (10). Another point indicating that it is not just the difference in organism that dictates the combination of CDEs and CHRs results from the fact that in most transfections of reporter constructs for cell cycle assays mouse NIH 3T3 cells are used irrespective of the origin of the gene.
###end p 56
###begin p 57
###xml 63 71 63 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin A</italic>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc2</italic>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c12">12</xref>
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B-myb</italic>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c35">35</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c36">36</xref>
###xml 396 402 396 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 735 736 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 773 779 773 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 390 395 <span type="species:ncbi:10090">mouse</span>
CDE sequences display some homology to E2F sites. In fact, for cyclin A and cdc2 it has been described that E2F can bind to CDEs in the promoters (12). Furthermore, in the B-myb promoter a CHR-like element, named the downstream repression site, was identified to regulate cell cycle-dependent transcription together with an E2F site (35,36). Therefore, we tested if the isolated CHR in the mouse cdc25C promoter can cooperate with an E2F site. Transcriptional up-regulation during the cell cycle by this hybrid E2F/CHR is even more pronounced than with wild-type CHR element alone (Fig. 5B). Still, this regulation is dependent on the CHR since its mutation leads to a drop of cell cycle transcription despite an intact E2F site (Fig. 5B, mutant M14). We conclude that the cdc25C CHR can cooperate with an E2F site.
###end p 57
###begin p 58
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 385 386 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
###xml 434 440 434 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 561 562 561 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f7">7</xref>
###xml 626 633 626 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Originally thought of as a negative control we created two constructs that yielded Sp1/3 sites upstream from the CHR (mutants M15 and M16). Surprisingly, the two mutant promoters did slightly better in up-regulating cell cycle-dependent stimulation of transcription (Fig. 5B), different from promoters with other mutations in this region which show a moderate loss of regulation (Fig. 5A, mutants M1 to M4). Both Sp1/3 mutants of the cdc25C promoter (M15 and M16) are able to bind Sp1 and Sp3 proteins. Also the E2F mutants M13 and M14 bind well to Sp1/3 (Fig. 7A and B). This suggests that Sp1 and Sp3 proteins can also bind in vivo to this region adjacent to the central regulator site CHR, implying that E2F as well as Sp1/3 sites can cooperate with the CHR in cell cycle-regulated transcription.
###end p 58
###begin p 59
###xml 189 205 189 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">thymidine kinase</italic>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c37">37</xref>
###xml 367 375 367 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin E</italic>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c38">38</xref>
###xml 578 601 578 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dihydrofolate reductase</italic>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c19">19</xref>
###xml 627 633 627 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 759 775 759 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">thymidine kinase</italic>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c18">18</xref>
###xml 867 876 867 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 922 924 922 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c20">20</xref>
###xml 979 985 979 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1083 1084 1083 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f6">6</xref>
###xml 1178 1192 1178 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DNA polymerase</italic>
###xml 1205 1207 1205 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c39">39</xref>
###xml 361 366 <span type="species:ncbi:10090">mouse</span>
###xml 753 758 <span type="species:ncbi:10090">mouse</span>
###xml 861 866 <span type="species:ncbi:9606">human</span>
Sp1/3 had earlier been implicated in cell cycle transcription but never in conjunction with CDE/CHR regulation. For example, binding of Sp1/3 to a GC element has been shown for the hamster thymidine kinase promoter which is necessary for growth-related transcription from this promoter (37). Furthermore, it has been shown that Sp1 and E2F sites overlap in the mouse cyclin E promoter and have an antagonistic effect on transcriptional activity (38). It has been found that pRb can form complexes with Sp1 during all phases of the cell cycle. This complex activates the hamster dihydrofolate reductase promoter (19). Karlseder et al. showed that cooperation between E2F and Sp1 is necessary for general activity of growth-dependent transcription of the mouse thymidine kinase promoter (18). Sp1 binding sites are necessary for E2F-1-dependent repression of the human cyclin D1 promoter. E2F-1 can act through an Sp1 site (20). To a limited extent this could also be the case for cdc25C transcription since we observe a weak binding of E2F also to the Sp1/3 mutants M16 and M17 (Fig. 6). Recently, cooperation between Sp1 and E2F sites has been reported in a promoter regulating DNA polymerase expression (39). In summary, it appears to be a novel finding that Sp1/3 sites can substitute for the CDE in a CDE/CHR tandem element.
###end p 59
###begin p 60
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f5">5</xref>
Generally, standard deviations in experiments presented in Figure 5 are relatively large. The reason is that we have performed several completely independent experiments and included them in these results. Therefore, variations stemming from, for example, synchronization of cells, transfections and luciferase measurements are the cause for these standard deviations. In particular, quality of synchronization varies to a large extent from one experiment to another. Because of these strong potential variations we refrained from just presenting several measurements from experiments carried out in parallel with just one representative synchronization.
###end p 60
###begin p 61
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25</italic>
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25B</italic>
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25B</italic>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkf306c40">40</xref>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 347 348 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkf306f2">2</xref>
###xml 57 62 <span type="species:ncbi:10090">mouse</span>
The regulatory region of other cdc25 genes, like that of mouse cdc25B, are different from that of cdc25C. The cdc25B promoter contains a TATA box and its transcription during the cell cycle is, in part, mediated by a cell cycle-regulated repressor (40). The two sites overlap and are different from the CHR described for the cdc25C promoter (Fig. 2).
###end p 61
###begin p 62
In summary, it becomes evident that the CHR can act as a single element in cell cycle-dependent transcription or function in tandem with CDE, E2F or Sp1/3 sites. It appears that E2F, Sp1 and Sp3 proteins can cooperate with the protein binding to the CHR. So far this factor has eluded identification. From the work described here it is obvious that a priority of future work will be to elucidate the identity of this transcriptional regulator and analyze its interactions with other factors.
###end p 62
###begin title 63
SUPPLEMENTARY MATERIAL
###end title 63
###begin p 64
Supplementary Material is available at NAR Online.
###end p 64
###begin title 65
[Supplementary Material]
###end title 65
###begin title 66
Figures and Tables
###end title 66
###begin p 67
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 380 381 380 381 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 471 477 471 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 481 490 481 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin B2</italic>
###xml 566 573 566 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
###xml 760 766 760 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 787 796 787 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin B2</italic>
###xml 850 851 850 851 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
 Cell cycle-dependent expression from the mouse cdc25C promoter. NIH 3T3 mouse fibroblast cells were transfected with m25C-wt-luci or B2-luci plasmids. Cells were cultured for 24 h after transfection and then serum starved for 60 h. For the 0 h time points, resting cells after serum starvation were used, whereas the other time points are after addition of serum to the medium. (A) Samples from parallel experiments were analyzed for luciferase expression driven by the cdc25C or cyclin B2 promoters. Within a time point activities were normalized to expression of Renilla luciferase. The highest expression level for each plasmid measured by luciferase activity was set at 100% and other values were normalized to that. 890 relative light units (r.l.u.) for cdc25C and 2056 r.l.u. for cyclin B2 represent 100%. Assays were carried out four times. (B) In parallel, cells were analyzed for their DNA content by FACS at different times to determine their cycle distribution of the cell population used in the reporter assays.
###end p 67
###begin p 68
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 680 686 680 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
###xml 262 267 <span type="species:ncbi:9606">human</span>
###xml 612 617 <span type="species:ncbi:10090">mouse</span>
###xml 664 669 <span type="species:ncbi:10090">mouse</span>
###xml 674 679 <span type="species:ncbi:9606">human</span>
 Limited homology between mouse and human cdc25C promoters indicates potential regulatory sites. The mouse cdc25C upstream region was cloned after amplification by primer walking and sequenced (GenBank accession no. AF450244). This sequence is compared with the human cdc25C promoter for which some regulatory sites have been mapped (GenBank accession nos AY046902 and Z29077). GC boxes binding Sp1 and Sp3 transcription factors, CCAAT boxes contacted by NF-Y trimeric proteins and the CDE and CHR cell cycle regulatory elements are indicated. Numbering starts at the first coding nucleotide triplet. A complete mouse promoter sequence with a longer comparison of mouse and human cdc25C promoters is given in the Supplementary Material.
###end p 68
###begin p 69
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 136 142 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 258 265 258 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
###xml 474 481 474 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla</italic>
 NF-Y is the main activator for cdc25C transcription. Increasing amounts of dominant-negative NF-YA subunit down-regulate the wild-type cdc25C luciferase reporter construct. Firefly luciferase reporter m25C-wt-luci, together with pRL-null plasmid expressing Renilla luciferase control, was transfected in NIH 3T3 cells. Increasing amounts of a plasmid coding for a dominant-negative form of NF-YA, YA13m29, were co-transfected. Firefly luciferase activity was normalized to Renilla luciferase. The value for transfections without YA13m29 was set at 100% and other activities are given relative to that. Three independent experiments were carried out with three assays per experiment and standard deviations are shown.
###end p 69
###begin p 70
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 112 117 <span type="species:ncbi:10090">mouse</span>
 Wild-type p53 down-regulates transcription from the cdc25C promoter. SaOS-2 cells were co-transfected with the mouse cdc25C-promoter reporter and wild-type or transcriptionally inactive mutant p53-expressing plasmids. Luciferase activity was measured from lysates. Experiments were carried out in triplicate and standard deviations are shown .
###end p 70
###begin p 71
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 292 298 292 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 1118 1119 1118 1119 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1189 1190 1189 1190 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
 Cell cycle-dependent transcription from wild-type and mutant cdc25C promoter luciferase constructs. Dominant importance of the CHR for cell cycle-dependent transcription. The CHR can cooperate with Sp1/3, CDE or E2F sites. Stimulation rates represent transcriptional regulation of wild-type cdc25C and mutant promoters during the cell cycle. NIH 3T3 cells were transfected with wild-type (wt) or mutant m25C-luci constructs, grown for 24 h, starved by serum deprivation and restimulated to enter the cell cycle. Cell lysates were assayed for luciferase activity. Wild-type and mutant constructs were tested in parallel experiments. Stimulation of promoter activity during the cell cycle was calculated by dividing luciferase activities 24 h after serum addition by activities before serum stimulation. Stimulation for wt-m25C-luci was set as 100% and percentages for mutants were calculated for every experiment relative to this stimulation. Average stimulation for wild-type was 13.6-fold. Experiments were repeated between two and six times for each individual mutant. Standard deviations are shown in the graphs. (A) Mutational analysis of the CHR and the region upstream of the CHR. (B) Analysis of bona fide CDE, E2F or Sp1/3 sites introduced upstream of the CHR. M12 represents a CDE and M13 represents an E2F site, M15 and M16 represent Sp1/3 sites, respectively. E2F/CHR or Sp1/3-CHR hybrid sites with additional mutations in the CHR, as in mutant M6, were analyzed with mutants M14 and M17, respectively.
###end p 71
###begin p 72
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B-myb</italic>
###xml 321 327 321 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
 E2F/DP heterodimers cannot bind to the wild-type cdc25C promoter but form complexes on E2F/CHR sites. EMSAs with recombinant E2F-1-GST and DP-1-His proteins were carried out with probes from the B-myb promoter as controls (myb and myb mut). Sequences of wild-type and mutant oligonucleotides used to test binding to the cdc25C promoter can be derived from Figure 5.
###end p 72
###begin p 73
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 242 248 242 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 302 308 302 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 372 373 372 373 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 434 440 434 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 459 460 459 460 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 558 559 558 559 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 623 629 623 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25C</italic>
###xml 236 241 <span type="species:ncbi:10090">mouse</span>
###xml 617 622 <span type="species:ncbi:10090">mouse</span>
 Binding of Sp1 and Sp3 proteins to the mutants of the cdc25C promoter tested by EMSA. Nuclear extracts from HeLa cells were employed to test for binding of Sp1 and Sp3 proteins to wild-type and mutant oligonucleotides derived from the mouse cdc25C promoter. The GC probe was used as positive control. cdc25C mutant probes follow the same nomenclature given in Figure 5. (A) EMSA with GC control oligonucleotide, wild-type and mutant cdc25C promoter probes. (B) EMSA bands representing Sp1 or Sp3 shifts are identified by reaction with specific antibodies. (C) The Sp25C oligonucleotide represents a segment from the mouse cdc25C promoter upstream of the CHR and NF-Y binding sites probing for Sp1/3 binding (Fig. 2). GC probe and Sp1-specific antibody serve as reagents to identify Sp1/3 proteins.
###end p 73
###begin title 74
ACKNOWLEDGEMENTS
###end title 74
###begin p 75
We thank Kristian Helin, Reinhard Luhrmann, Roberto Mantovani and Bert Vogelstein for generously providing reagents, Jana Lorenz for expert technical assistance and Christine Lange-zu Dohna for help in the initial phase of this project. K.R. is a recipient of a graduate fellowship awarded by the Freistaat Sachsen. K.E. is supported by grants from the Bundesministerium fur Bildung und Forschung through the IZKF and the Deutsche Forschungsgemeinschaft.
###end p 75
###begin title 76
REFERENCES
###end title 76

